A paradigm shift in how we treat pediatric low-grade glioma-Targeting the molecular drivers
Neuro Oncol
.
2024 Apr 5;26(4):593-595.
doi: 10.1093/neuonc/noae008.
Authors
David S Ziegler
1
2
3
,
Rebecca Lehmann
1
2
,
David D Eisenstat
4
5
6
Affiliations
1
Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney, New South Wales, Australia.
2
School of Clinical Medicine, UNSW Medicine & Health, UNSW Sydney, Sydney, New South Wales, Australia.
3
Kids Cancer Centre, Sydney Children's Hospital, Randwick, New South Wales, Australia.
4
Children's Cancer Centre, Royal Children's Hospital, Parkville, Victoria, Australia.
5
Murdoch Children's Research Institute, Parkville, Victoria, Australia.
6
Department of Paediatrics, University of Melbourne, Parkville, Victoria, Australia.
PMID:
38243845
PMCID:
PMC10995501
(available on
2025-01-19
)
DOI:
10.1093/neuonc/noae008
No abstract available
Publication types
Research Support, Non-U.S. Gov't
MeSH terms
Brain Neoplasms* / genetics
Brain Neoplasms* / therapy
Child
Glioma* / genetics
Glioma* / therapy
Humans
Grants and funding
2019056/National Health and Medical Research Council
Cancer Institute New South Wales Program
IPAP2023/0929/Perpetual Limited
2019-1193/Royal Children's Hospital Foundation